UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1450-1
Program Prior Authorization/Notification
Medications Demser® (metyrosine)
P&T Approval Date 7/2024
Effective Date 1/1/2025
1. Background:
Demser is indicated in the treatment of patients with pheochromocytoma for preoperative
preparation of patients for surgery, management of patients when surgery is contraindicated, and
the chronic treatment of patients with malignant pheochromocytoma. Demser is not
recommended for the control of essential hypertension.
2. Coverage Criteriaa:
A. Initial Authorization
1. Demser will be approved based on the following criterion:
a. Diagnosis of pheochromocytoma
Authorization will be issued for 12 months.
B. Reauthorization
1. Demser will be approved based on the following criterion:
a. Documentation of positive clinical response to therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Demser [package insert]. Bridgewater, NJ: Bausch Health, LLC; July 2021.
© 2024 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification – Demser
Change Control
7/2024 New program.
© 2024 UnitedHealthcare Services, Inc.
2